Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

C011 - Dermatology Review: Skin Cancer, Surgical, and Cosmetic

Saturday, February 17; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • 1. Recognize new developments in surgical and cosmetic dermatology.
  • 1. Evaluate new treatment options for skin cancer.
  • 1. Analyze and describe best practices for surgical and cosmetic dermatology.

Description

This course will comprehensively review new developments in medical, cosmetic and surgical dermatology. Innovation in diagnosis and treatment of common dermatologic conditions, such as skin cancer, actinic keratosis, psoriasis, eczema, acne, contact dermatitis, infectious diseases in dermatology, and rosacea will be reviewed. New developments in cosmetic dermatology and best practices in surgical and cosmetic dermatology will be reviewed. Practice management, including billing, coding, electronic health records, and new payment models.

Disclosures

  • Bhatia, Neal D., MD: Aclaris Therapeutics, Inc. – I(Grants/Research Funding); Actavis – I(Grants/Research Funding); Allergan, Inc – C(H); Almirall – C(H); Aqua – C(H); Asana Biosciences, LLC – I(Grants/Research Funding); Atacama Therapeutics – I(Grants/Research Funding); Bayer Pharmaceuticals – C(H); Biofrontera AG – C(H); BioPharmX – I(Grants/Research Funding); Brickell Biotech, Inc. – I(Grants/Research Funding); Cipher Pharmaceuticals – C(H); Crown Laboratories, Inc. – I(Grants/Research Funding); Cutanea Life Sciences – I(Grants/Research Funding); Dermira – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – I(Grants/Research Funding); Ferndale Laboratories, Inc. – C(H); Foamix – I(Grants/Research Funding); Galderma Laboratories, L.P. – C(H); Glenmark Generics Inc. – I(Grants/Research Funding); IntraDerm Pharmaceuticals – C(H); ISDIN – C(H); La Roche-Posay Laboratorie Pharmaceutique – C(H); LEO Pharma, US – I(Grants/Research Funding); Mayne Pharma Group – C(H); MC2 Therapeutics – I(Grants/Research Funding); Menlo Therapeutics – I(Grants/Research Funding); Mylan Technologies Inc. – C(H); Novartis Pharmaceuticals Corp. – C(H); Ortho Dermatologics – C(H); Par Pharmaceutical – I(Grants/Research Funding); Perrigo Company – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Pierre Fabre Dermo-Cosmétique US – C(H); Promius Pharma, LLC – A(H); Realm Therapeutics – I(Grants/Research Funding); Sanofi/Regeneron – C(H), I(Grants/Research Funding); Sienna Biopharmaceuticals – I(Grants/Research Funding); Skinfix, Inc. – A(H); Sol-Gel Technologies – I(Grants/Research Funding); Soligenix, Inc – I(Grants/Research Funding); Strata Skin Sciences – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H); Valeant Pharmaceuticals International – C(H); Viamet Pharmaceuticals, Inc – I(Grants/Research Funding); Vidac Pharma – I(Grants/Research Funding); Vyome Biosciences – I(Grants/Research Funding);
  • Brown, Marc D., MD: Castle Biosciences – A(Fees);
  • Ceilley, Roger I., MD: Biofrontera AG – A(H); Ferndale Laboratories, Inc. – A(H); Pfizer Inc. – A(H); Sun Pharmaceutical Industries Ltd. – A(H);
  • Cockerell, Clay J., MD: Castle Biosciences, Inc – C(H); Cockerell Dermatology Management, LLC – F(NC); PTV – A(NC); Sensus Healthcare – C(NC); TopMD – F(NC);
  • Cohen, Joel Lee, MD: Allergan, Inc. – C(H), I(Grants/Research Funding); Galderma USA – C(H), I(Grants/Research Funding); LEO Pharma, US – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – C(H); Revance Therapeutics, Inc. – I(Grants/Research Funding); Sciton Inc. – C(H);
  • Desai, Seemal R., MD: AbbVie – C(Fees), I(Grants/Research Funding), SP(H); Allergan, Inc – C(Fees); Anacor Pharmaceuticals, Inc. – C(Fees); Dermira – I(Grants/Research Funding); Dr. Reddy – I(Grants/Research Funding); Ferndale Laboratories, Inc. – A(Fees); Foamix – I(Grants/Research Funding); Galderma Laboratories, LP – C(Fees), SP(H); Innovaderm Research Inc. – I(Grants/Research Funding); Menlo Therapeutics – C(H), I(Grants/Research Funding); Novan – I(Grants/Research Funding); Par Pharmaceutical – I(Grants/Research Funding); Pfizer Inc. – SP(H); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Symbio – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – C(Fees), SP(H);
  • Draelos, Zoe Diana, MD: Abbott Laboratories – I(Grants/Research Funding); Actavis – I(Grants/Research Funding); AGI Dermatics – I(Grants/Research Funding); Allergan, Inc. – I(Grants/Research Funding); AmDerma Pharmaceuticals, LLC – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Amneal Pharmaceuticals, LLC – I(Grants/Research Funding); AstraZeneca – I(Grants/Research Funding); Avon Products, Inc. – I(Grants/Research Funding); Bayer – I(Grants/Research Funding); Bayer Consumer Healthcare Pharmaceuticals – I(Grants/Research Funding); Beiersdorf, Inc. – I(Grants/Research Funding); Boots – C(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Chattem, Inc. – I(Grants/Research Funding); Colgate-Palmolive – I(Grants/Research Funding); Dermira – I(Grants/Research Funding); Dial Corporation – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Elizabeth Arden – I(Grants/Research Funding); Exeltis – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding); GlaxoSmithKline – I(Grants/Research Funding); Glenmark Generics Inc. – I(Grants/Research Funding); Guthy-Renker – I(Grants/Research Funding); Helix BioMedix – I(Grants/Research Funding); Johnson & Johnson Consumer Products Company – I(Grants/Research Funding); Kao Brands – I(Grants/Research Funding); Kimberly Clark – I(Grants/Research Funding); Kythera – I(Grants/Research Funding); L'Oreal USA Inc. – I(Grants/Research Funding); La Roche-Posay Laboratoire Pharmaceutique – I(Grants/Research Funding); Lexington International LLC – I(Grants/Research Funding); Living Proof, Inc – I(Grants/Research Funding); Lumity – I(Grants/Research Funding); MakuCell, Inc. – I(Grants/Research Funding); Maruho Co., Ltd – I(Grants/Research Funding); Medicis Pharmaceutical Corporation – I(Grants/Research Funding); Merck & Co., Inc. – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); Mimetica Pty. Limited – I(Grants/Research Funding); Neocutis – I(Grants/Research Funding); Neutrogena Corporation – I(Grants/Research Funding); Niadyne – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Nuskin – I(Grants/Research Funding); Oculus – I(Grants/Research Funding); Onset Therapeutics – I(Grants/Research Funding); Otsuka Pharmaceutical Co., Ltd. – I(Grants/Research Funding); Pacific Biosciences – I(Grants/Research Funding); Perrigo Company – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Procter & Gamble Company – I(Grants/Research Funding); Promius Pharma, LLC – I(Grants/Research Funding); Quinnova Pharmaceuticals, Inc. – I(Grants/Research Funding); Ranbaxy Laboratories Limited – I(Grants/Research Funding); RECKITT BENCKISER (ESPAÑA), S.L. – I(Grants/Research Funding); Revance Therapeutics, Inc. – I(Grants/Research Funding); Revision Skincare – I(Grants/Research Funding); Signum Biosciences, Inc. – I(Grants/Research Funding); SkinMedica, Inc. – I(Grants/Research Funding); Sun Products Corporation – I(Grants/Research Funding); Suneva Medical, Inc. – I(Grants/Research Funding); Symrise – I(Grants/Research Funding); Syneron, Inc. – I(Grants/Research Funding); Taro Pharm – I(Grants/Research Funding); Teva Pharmaceuticals USA – I(Grants/Research Funding); Tolmar – I(Grants/Research Funding); Valeant Pharmaceuticals International – I(Grants/Research Funding); Vichy Laboratoires – I(Grants/Research Funding);
  • Glaser, Dee Anna, MD: Allergan, Inc. – I(Grants/Research Funding), O(H); Dermira – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H); Galderma Research & Development, LLC – I(Grants/Research Funding); Miramar Labs – C(H); Revance Therapeutics, Inc. – I(Grants/Research Funding); Unilever Home & Personal Care USA – A(H);
  • Goldenberg, Gary, MD: AbbVie – SP(H); Allergan, Inc – C(H); Anacor Pharmaceuticals, Inc. – C(H); Bayer – SP(H); Bayer Pharmaceuticals – C(H); Castle Biosciences – SP(H); Celgene Corporation – C(H), SP(H); Dermira – A(H); Eclipse Medical – C(H); Eli Lilly and Company – C(Fees), SP(H); Galderma USA – SP(H); Genentech, Inc. – C(H); Janssen Pharmaceuticals, Inc – C(H); Leo Pharma A/S – I(Grants/Research Funding); LEO Pharma, US – C(H), SP(H); MelaSciences – C(H); Novartis Pharmaceuticals Corp. – C(H), SP(H); Pfizer Inc. – C(H); Pharmaderm – A(H), I(Grants/Research Funding), SP(H); Ranbaxy Laboratories Limited – C(H); Stiefel a GSK company – C(H), I(Grants/Research Funding); Taro Pharm – C(Fees); Teva Pharmaceuticals USA – C(Fees); Valeant Pharmaceuticals North America LLC – C(H), I(Grants/Research Funding), SP(H); Xoft – C(H);
  • Moy, Ronald L., MD: DNA EGF Renewal – F(NC);
  • Olbricht, Suzanne, MD: no financial relationships exist with commercial interests.
Schedule
Saturday, February 17
9:00 AM
Dr. Desai / Cosmetic treatment in skin of color
9:15 AM
Dr. Moy / Combining surgical and cosmetic procedures for optimal scarring
9:30 AM
Dr. Olbricht / Squamous Cell Carcinoma Update
9:45 AM
Dr. Draelos / Update on Cosmeceuticals in dermatology
10:00 AM
Dr. Goldenberg / PRP and Stem Cells – Role of regenerative medicine in dermatology
10:15 AM
Dr. Goldenberg, Dr. Desai, Dr. Moy, Dr. Olbricht, and Dr. Draelos / Q&A
10:30 AM
Dr. Cohen / Safety Considerations for Soft Tissue Fillers
10:45 AM
Dr. Cockerell / Diagnosis and treatment of melanocytic lesions in 2018
11:00 AM
Dr. Brown / Non-surgical treatment of skin cancer in 2018
11:15 AM
Dr. Glaser / Advances in toxins and fillers
11:30 AM
Dr. Bhatia / New Approaches to Treating NMSC
11:35 AM
Dr. Cohen, Dr. Cockerell, Dr. Brown, Dr. Glaser, and Dr. Bhatia / Q&A
Event Details
  • Date
    Saturday, February 17
  • Time
    9:00 AM - 12:00 PM
  • Location
    Room 30E
  • CME Credits
    3.00
  • Type
    Ticketed
Directors/Co-Directors
  • Gary Goldenberg, MD, FAAD
Speakers
  • Clay J. Cockerell, MD, FAAD - Handout
  • Dee Anna Glaser, MD, FAAD
  • Joel Lee Cohen, MD, FAAD - Handout
  • Marc D. Brown, MD, FAAD
  • Neal D. Bhatia, MD, FAAD - Handout
  • Roger I. Ceilley, MD, FAAD - Handout
  • Ronald L. Moy, MD, FAAD
  • Seemal R. Desai, MD, FAAD
  • Suzanne Olbricht, MD, FAAD - Handout
  • Zoe Diana Draelos, MD, FAAD